Key Drivers
- High profitability
- Heavy operating spend
- Low leverage
AIAI Summary
Acadia has become a commercially driven, high‑margin franchise with >$1B in recurring revenue that materially de‑risks near‑term valuation, but treat it as an event‑driven stock—monitor quarterly FCF, prescription persistence/penetration versus rising SG&A, and the trofinetide CHMP re‑examination plus 2026–27 readouts as binary catalysts that will rapidly re‑rate the shares.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Heavy operating spend
- •Low leverage
ACAD combines very high gross/net margins, strong ROE/ROIC, low leverage and positive annual FCF but is weighed down by heavy R&D/SG&A, large working capital/investments and rich valuation that assumes continued growth.
Price Behavior
Key Price Behavior Insights:
- •Below last month
- •Near support test
- •~13% decline
ACAD is in a short‑term downtrend—trading below the last month mean (~$22.60) after a ~13–14% drop, testing support near $20.30 with a small bounce to $20.74 that could be a brief buyers' probe.
~13–14% fall from late
Sentiment & News
Key News Insights:
- •Billion‑dollar revenue
- •Trofinetide setback
- •Active late‑stage pipeline
Acadia topped $1B in revenue with Q4 EPS beats and $1.22–$1.28B 2026 guidance but faces EU regulatory risk on trofinetide amid an active late‑stage pipeline and ongoing investor interest.
Strong commercial performance and guidance support valuation, but EU regulatory uncertainty for trofinetide raises near‑term risk until re‑examination and upcoming readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings